Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 13/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632684 | 0.83 | MAOB (0.39) | RXRAGRIN1GRIN2BHDAC1HDAC6 | |
| SCHEMBL190181 | 0.80 | MAOB (0.55) | MAOBMAOA | |
| SCHEMBL29468641 | 0.78 | SMN1; SMN2 (0.46) | GRIN2BMAOBMAOA | |
| SCHEMBL8251097 | 0.78 | MAOB (0.57) | HDAC6MAOBMAOA | |
| SCHEMBL30065009 | 0.78 | MAOB (0.57) | HDAC6MAOBMAOA | |
| SCHEMBL29468690 | 0.77 | CYP4F2 (0.42) | HDAC1HDAC6HDAC5MAOBMAOA | |
| SCHEMBL29468740 | 0.77 | HSD17B10 (0.49) | MAOA | |
| SCHEMBL16769687 | 0.76 | SLC6A4 (0.40) | — | |
| SCHEMBL29468828 | 0.75 | RXRA (0.40) | RXRAGRIN1GRIN2B | |
| SCHEMBL15615099 | 0.74 | MAOB (0.42) | HDAC1HDAC6HDAC5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| WO-2015077866-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158697-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | RXRA 4763/4885GRIN1 3646/4885GRIN2B 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.